Clinical trials: Unresectable Gastric Carcinoma
Unresectable Gastric Cancer
A Retrospective Study of Immunotherapy in Conversion Therapy of Unresectable Gastric Cancer
This study was an observational, non-interventional, multicenter retrospective study to evaluate the feasibility and safety of sintilimab combined with chemotherapy (SOX or PS) in the clinical practice of unresectable locally…
- Trial name
- NCT05385809
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer, Bleeding
The Use of Proton Pump Inhibitor on the Prevention of Gastric Cancer Bleeding
The aim of this study is the effect of proton pump inhibitor (PPI) with respect to gastric cancer bleeding in inoperable patients.
- Trial name
- NCT02150447
- Testing
- Proton pump inhibitor
- Where
- 4 sites in South Korea
- Volunteers
- 394 people
- Sponsor
- National Cancer Center, Korea
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
This phase 2 trial evaluates the benefit of epacadostat plus pembrolizumab in combination to treat patients with gastroesophageal junction or gastric cancer that has spread to other parts of the body and cannot be removed by…
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma
- Trial name
- NCT03196232
- Testing
- Epacadostat, Pembrolizumab
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- George Albert Fisher
Gastric Cancer
Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer
To investigate the clinical efficacy and safety of envollizumab combined with fruquintinib and SOX versus SOX in conversion therapy for patients with Her-2 negative, unresectable locally advanced gastric cancer.
- Trial name
- NCT05914610
- Testing
- Envolimab, Fruquintinib, Oxaliplatin
- Volunteers
- 100 people
- Sponsor
- Fujian Medical University
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Capecitabine, Epirubicin, and Carboplatin in Treating Patients With Progressive, Unresectable, or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, epirubicin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer
- Trial name
- NCT00486356
- Testing
- capecitabine, carboplatin, epirubicin hydrochloride
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Nebraska
Gastric Cancer
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
This study is to compare and evaluate the efficacy and safety of the treatment with ONO-4578 in combination with nivolumab and chemotherapy with those of the treatment with placebo in combination with nivolumab and chemotherapy…
- Trial name
- NCT06256328
- Testing
- ONO-4578, Oxaliplatin, Capecitabine
- Where
- 63 sites in Japan, South Korea and 1 more
- Volunteers
- 226 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Gastric Cancer
XParTS II: Capecitabine/CDDP(XP) and S-1/CDDP(SP) as the First-line Treatment for Advanced Gastric Cancer
The aim of this study is to elucidate the efficacy and safety of XP and SP for first-line treatment of Advanced Gastric Cancer.
- Trial name
- NCT01406249
- Testing
- SP, XP
- Where
- Japan
- Volunteers
- 100 people
- Sponsor
- Epidemiological and Clinical Research Information Network
Gastroesophageal Junction Adenocarcinoma, Stomach Adenocarcinoma
Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
This study aims to evaluate the efficacy and safety of Sintilimab plus CAPOX in the conversion therapy for patients with unresectable locally advanced or limited metastatic adenocarcinoma of the stomach or esophagogastric junction
- Conditions
- Gastroesophageal Junction Adenocarcinoma, Stomach Adenocarcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Metastatic Gastric Cancer
- Trial name
- CTSCAPOXSEA (NCT04263870)
- Testing
- sintilimab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sichuan University
HER2-positive Gastric Cancer, Metastatic Gastric Cancer
First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)
This is a Phase II, randomized, multicenter, open-label clinical trial designed to compare Disitamab Vedotin plus Sintilimab and S-1 with Trastuzumab plus chemotherapy ± Sintilimab for first-line treatment of HER2-Positive…
- Conditions
- HER2-positive Gastric Cancer, Metastatic Gastric Cancer, Unresectable Gastric Carcinoma
- Trial name
- NCT06730373
- Testing
- Disitamab Vedotin, Sintilimab, S-1
- Where
- 20 sites in China
- Volunteers
- 110 people
- Sponsor
- Qilu Hospital of Shandong University
Gastric Cancer
Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer
This study aims to evaluate the efficacy of disitamab vedotin in combination with sintilimab and SOX as conversion therapy in patients with initially unresectable locally advanced or metastatic gastric cancer exhibiting HER2 IHC…
- Trial name
- Remission (NCT07194005)
- Testing
- Disitamab vedotin(RC48), Sintilimab, S-1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Esophageal Cancer, Gastric Cancer
Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas
This study is for patients with esophageal, esophagogastric, or gastric cancer that has spread to other parts of the body. The purpose of this study is to test the safety and effectiveness of a new experimental drug called ZD…
- Trial name
- NCT00215995
- Testing
- Cisplatin, Irinotecan, ZD 1839
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors.
- Conditions
- Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05365581
- Testing
- ASP2138, Pembrolizumab, Oxaliplatin
- Where
- 46 sites in United States, China and 6 more
- Volunteers
- 398 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Gastric Adenocarcinoma
Dose-dense Biweekly Docetaxel Combined With 5-fluorouracil as First-line Treatment in Advanced Gastric Cancer
This is an open-label, phase II study to evaluate the efficacy and safety of biweekly docetaxel and DeGramont regimen on unresectable gastric adenocarcinoma in the first-line therapy.
- Trial name
- DaeMon (NCT01567618)
- Testing
- Docetaxel, Fluorouracil
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Stomach Cancer
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy
KN026-001 is a two-stage study (Open-label stage/Randomized stage). Open-label stage is designed to evaluate the safety and efficacy of KN026 and chemotherapy when given together.
- Trial name
- NCT05427383
- Testing
- KN026/Placbo Injection, Paclitaxel Injection, Docetaxel Injection
- Where
- China
- Volunteers
- 286 people
- Sponsor
- Shanghai JMT-Bio Inc.
Adenocarcinoma Gastric Stage IV With Metastases, Adenocarcinoma - GEJ
DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)
This study will find out if trastuzumab deruxtecan is safe and works for participants with gastric or gastroesophageal junction cancer.
- Trial name
- NCT04014075
- Testing
- Trastuzumab deruxtecan
- Where
- 37 sites in United States, Belgium and 3 more
- Volunteers
- 79 people
- Sponsor
- Daiichi Sankyo
Gastric Cancer
A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment
An open study to evaluate the safety of apatinib mesylate (YN968D1) 1,000mg monotherapy in patients with unresectable locally advanced or metastatic Gastric cancer failed to standard therapy.
- Trial name
- NCT02711969
- Testing
- Apatinib mesylate
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Bukwang Pharmaceutical
First-line Treatment for Patients With Non-resectable Gastric Cancer or Cancer of the Esophagus or
Chemotherapy for Patients With Cancer of the Stomach
The purpose of this study is to determine maximal tolerable dose (MTD) of the combination of docetaxel, oxaliplatin and S1 (DOS) to patients with gastric cancer.
- Trial name
- DOS (NCT01928524)
- Testing
- DOS2w Dose level 1A, DOS2w Dose level 2A, DOS2w Dose level 3A
- Where
- Denmark
- Volunteers
- 34 people
- Sponsor
- Per Pfeiffer